We developed a potent, selective, orally administered heterobifunctional IRAK4 degrader, KT-474 (SAR444656), which demonstrated consistent effects on target expression, biomarkers of inflammation and clinical endpoints in a phase 1 placebo-controlled trial in HVs with an open-label cohort of patients with HS and patients with AD. This evidence concerns the gene IRAK4 and Alzheimer disease.